TY - JOUR AU - Dailey, G. PY - 2011 DA - 2011// TI - Overall mortality in diabetes mellitus: where do we stand today? JO - Diabetes Technol Ther VL - 13 ID - Dailey2011 ER - TY - JOUR AU - Barnett, K. N. PY - 2010 DA - 2010// TI - A 12-year follow-up study of all-cause and cardiovascular mortality among 10,532 people newly diagnosed with Type 2 diabetes in Tayside, Scotland JO - Diabet Med VL - 27 UR - https://doi.org/10.1111/j.1464-5491.2010.03075.x DO - 10.1111/j.1464-5491.2010.03075.x ID - Barnett2010 ER - TY - JOUR AU - Holman, R. R. PY - 2008 DA - 2008// TI - 10-year follow-up of intensive glucose control in type 2 diabetes JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0806470 DO - 10.1056/NEJMoa0806470 ID - Holman2008 ER - TY - JOUR AU - Bergenstal, R. M. PY - 2015 DA - 2015// TI - Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! JO - Diabetes Care VL - 38 UR - https://doi.org/10.2337/dc15-0099 DO - 10.2337/dc15-0099 ID - Bergenstal2015 ER - TY - BOOK PY - 2008 DA - 2008// TI - Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes PB - FDA CY - Silver Spring ID - ref5 ER - TY - BOOK PY - 2012 DA - 2012// TI - Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus PB - EMA CY - London ID - ref6 ER - TY - JOUR AU - Hirshberg, B. AU - Raz, I. PY - 2011 DA - 2011// TI - Impact of the US Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs JO - Diabetes Care VL - 34 UR - https://doi.org/10.2337/dc11-s202 DO - 10.2337/dc11-s202 ID - Hirshberg2011 ER - TY - JOUR AU - Schnell, O. PY - 2016 DA - 2016// TI - Current perspectives on cardiovascular outcome trials in diabetes JO - Cardiovasc Diabetol VL - 15 UR - https://doi.org/10.1186/s12933-016-0456-8 DO - 10.1186/s12933-016-0456-8 ID - Schnell2016 ER - TY - JOUR AU - Gerstein, H. C. PY - 2012 DA - 2012// TI - Basal insulin and cardiovascular and other outcomes in dysglycemia JO - N Engl J Med VL - 367 UR - https://doi.org/10.1056/NEJMoa1203858 DO - 10.1056/NEJMoa1203858 ID - Gerstein2012 ER - TY - JOUR AU - Marso, S. P. PY - 2017 DA - 2017// TI - Efficacy and safety of degludec versus glargine in Type 2 diabetes JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1615692 DO - 10.1056/NEJMoa1615692 ID - Marso2017 ER - TY - JOUR AU - Regier, E. E. AU - Venkat, M. V. AU - Close, K. L. PY - 2016 DA - 2016// TI - More than 7 years of hindsight: revisiting the FDA’s 2008 guidance on cardiovascular outcomes trials for Type 2 diabetes medications JO - Clin Diabetes VL - 34 UR - https://doi.org/10.2337/cd16-0005 DO - 10.2337/cd16-0005 ID - Regier2016 ER - TY - JOUR AU - Scirica, B. M. PY - 2013 DA - 2013// TI - Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1307684 DO - 10.1056/NEJMoa1307684 ID - Scirica2013 ER - TY - JOUR AU - White, W. B. PY - 2013 DA - 2013// TI - Alogliptin after acute coronary syndrome in patients with type 2 diabetes JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1305889 DO - 10.1056/NEJMoa1305889 ID - White2013 ER - TY - JOUR AU - Green, J. B. PY - 2015 DA - 2015// TI - Effect of sitagliptin on cardiovascular outcomes in Type 2 diabetes JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1501352 DO - 10.1056/NEJMoa1501352 ID - Green2015 ER - TY - JOUR AU - Pfeffer, M. A. PY - 2015 DA - 2015// TI - Lixisenatide in patients with Type 2 diabetes and acute coronary syndrome JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1509225 DO - 10.1056/NEJMoa1509225 ID - Pfeffer2015 ER - TY - JOUR AU - Marso, S. P. PY - 2016 DA - 2016// TI - Liraglutide and cardiovascular outcomes in Type 2 diabetes JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1603827 DO - 10.1056/NEJMoa1603827 ID - Marso2016 ER - TY - JOUR AU - Marso, S. P. PY - 2016 DA - 2016// TI - Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1607141 DO - 10.1056/NEJMoa1607141 ID - Marso2016 ER - TY - JOUR AU - Zinman, B. PY - 2015 DA - 2015// TI - Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504720 DO - 10.1056/NEJMoa1504720 ID - Zinman2015 ER - TY - JOUR AU - Marso, S. P. PY - 2016 DA - 2016// TI - Design of DEVOTE (trial comparing cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes at high risk of cardiovascular events)—DEVOTE 1 JO - Am Heart J VL - 179 UR - https://doi.org/10.1016/j.ahj.2016.06.004 DO - 10.1016/j.ahj.2016.06.004 ID - Marso2016 ER - TY - JOUR AU - Neal, B. PY - 2017 DA - 2017// TI - Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials JO - Diabetes Obes Metab VL - 19 UR - https://doi.org/10.1111/dom.12924 DO - 10.1111/dom.12924 ID - Neal2017 ER - TY - JOUR AU - Neal, B. PY - 2017 DA - 2017// TI - Canagliflozin and cardiovascular and renal events in Type 2 diabetes JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1611925 DO - 10.1056/NEJMoa1611925 ID - Neal2017 ER - TY - JOUR AU - Holman, R. R. PY - 2014 DA - 2014// TI - Rationale for and design of the acarbose cardiovascular evaluation (ACE) trial JO - Am Heart J VL - 168 UR - https://doi.org/10.1016/j.ahj.2014.03.021 DO - 10.1016/j.ahj.2014.03.021 ID - Holman2014 ER - TY - STD TI - Holman RR, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017. pii: S2213-8587(17)30309-1. ID - ref23 ER - TY - JOUR AU - Holman, R. R. PY - 2017 DA - 2017// TI - Effects of once-weekly exenatide on cardiovascular outcomes in Type 2 diabetes JO - N Engl J Med. VL - 377 UR - https://doi.org/10.1056/NEJMoa1612917 DO - 10.1056/NEJMoa1612917 ID - Holman2017 ER - TY - JOUR AU - Zinman, B. PY - 2017 DA - 2017// TI - Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2) JO - Diabetologia ID - Zinman2017 ER - TY - JOUR AU - Frontoni, S. PY - 2013 DA - 2013// TI - Glucose variability: an emerging target for the treatment of diabetes mellitus JO - Diabetes Res Clin Pract VL - 102 UR - https://doi.org/10.1016/j.diabres.2013.09.007 DO - 10.1016/j.diabres.2013.09.007 ID - Frontoni2013 ER - TY - JOUR AU - Heise, T. PY - 2004 DA - 2004// TI - Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes JO - Diabetes VL - 53 UR - https://doi.org/10.2337/diabetes.53.6.1614 DO - 10.2337/diabetes.53.6.1614 ID - Heise2004 ER - TY - JOUR AU - Wanner, C. PY - 2016 DA - 2016// TI - Empagliflozin and progression of kidney disease in Type 2 diabetes JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1515920 DO - 10.1056/NEJMoa1515920 ID - Wanner2016 ER - TY - JOUR AU - Watts, N. B. PY - 2016 DA - 2016// TI - Effects of canagliflozin on fracture risk in patients With Type 2 diabetes mellitus JO - J Clin Endocrinol Metab VL - 101 UR - https://doi.org/10.1210/jc.2015-3167 DO - 10.1210/jc.2015-3167 ID - Watts2016 ER - TY - STD TI - FDA Drug Safety Communication. FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density; 2015. ID - ref30 ER - TY - BOOK PY - 2016 DA - 2016// TI - FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) PB - FDA Drug Safety Communications CY - Silver Spring ID - ref31 ER - TY - JOUR AU - Fadini, G. P. AU - Avogaro, A. PY - 2017 DA - 2017// TI - SGTL2 inhibitors and amputations in the US FDA adverse event reporting system JO - Lancet Diabetes Endocrinol. VL - 5 UR - https://doi.org/10.1016/S2213-8587(17)30257-7 DO - 10.1016/S2213-8587(17)30257-7 ID - Fadini2017 ER - TY - STD TI - Agency EM. SGLT-2 inhibitors: information on potential risk of toe amputation to be included in prescribing information; 2017. ID - ref33 ER - TY - JOUR AU - Kosiborod, M. PY - 2017 DA - 2017// TI - Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study JO - Circulation. VL - 136 UR - https://doi.org/10.1161/CIRCULATIONAHA.117.029190 DO - 10.1161/CIRCULATIONAHA.117.029190 ID - Kosiborod2017 ER - TY - JOUR AU - Wu, J. H. PY - 2016 DA - 2016// TI - Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis JO - Lancet Diabetes Endocrinol VL - 4 UR - https://doi.org/10.1016/S2213-8587(16)00052-8 DO - 10.1016/S2213-8587(16)00052-8 ID - Wu2016 ER - TY - JOUR AU - Standl, E. PY - 2014 DA - 2014// TI - On the potential of acarbose to reduce cardiovascular disease JO - Cardiovasc Diabetol VL - 13 UR - https://doi.org/10.1186/1475-2840-13-81 DO - 10.1186/1475-2840-13-81 ID - Standl2014 ER - TY - JOUR AU - Ponikowski, P. PY - 2016 DA - 2016// TI - 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure JO - Rev Esp Cardiol (Engl Ed) VL - 69 UR - https://doi.org/10.1016/j.recesp.2016.10.014 DO - 10.1016/j.recesp.2016.10.014 ID - Ponikowski2016 ER - TY - JOUR AU - Rydén, L. PY - 2017 DA - 2017// TI - Corrections needed to 2016 ESC guideline and AHA scientific statement on heart failure JO - Lancet Diabetes Endocrinol VL - 5 UR - https://doi.org/10.1016/S2213-8587(17)30102-X DO - 10.1016/S2213-8587(17)30102-X ID - Rydén2017 ER - TY - JOUR AU - Griffin, S. J. AU - Leaver, J. K. AU - Irving, G. J. PY - 2017 DA - 2017// TI - Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes JO - Diabetologia ID - Griffin2017 ER - TY - JOUR AU - Petrie, J. R. PY - 2017 DA - 2017// TI - Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial JO - Lancet Diabetes Endocrinol VL - 5 UR - https://doi.org/10.1016/S2213-8587(17)30194-8 DO - 10.1016/S2213-8587(17)30194-8 ID - Petrie2017 ER - TY - JOUR AU - Standl, E. PY - 2017 DA - 2017// TI - Metformin in type 1 diabetes JO - Lancet Diabetes Endocrinol VL - 5 UR - https://doi.org/10.1016/S2213-8587(17)30216-4 DO - 10.1016/S2213-8587(17)30216-4 ID - Standl2017 ER - TY - JOUR AU - Vaccaro, O. PY - 2012 DA - 2012// TI - The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes JO - Diabetes Care VL - 35 UR - https://doi.org/10.2337/dc12-0954 DO - 10.2337/dc12-0954 ID - Vaccaro2012 ER - TY - JOUR AU - Vaccaro, O. PY - 2017 DA - 2017// TI - Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial JO - Lancet Diabetes Endocrinol VL - 35 ID - Vaccaro2017 ER - TY - JOUR AU - Dormandy, J. A. PY - 2005 DA - 2005// TI - Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial JO - Lancet VL - 366 UR - https://doi.org/10.1016/S0140-6736(05)67528-9 DO - 10.1016/S0140-6736(05)67528-9 ID - Dormandy2005 ER - TY - JOUR AU - Ridker, P. M. PY - 2017 DA - 2017// TI - Antiinflammatory therapy with canakinumab for atherosclerotic disease JO - N Engl J Med. VL - 377 UR - https://doi.org/10.1056/NEJMoa1707914 DO - 10.1056/NEJMoa1707914 ID - Ridker2017 ER - TY - JOUR AU - Standl, E. PY - 2017 DA - 2017// TI - Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes JO - Lancet Diabetes Endocrinol VL - 5 UR - https://doi.org/10.1016/S2213-8587(17)30033-5 DO - 10.1016/S2213-8587(17)30033-5 ID - Standl2017 ER - TY - JOUR AU - Leiter, L. A. PY - 2015 DA - 2015// TI - Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial JO - Diabetes Care VL - 38 UR - https://doi.org/10.2337/dc14-2868 DO - 10.2337/dc14-2868 ID - Leiter2015 ER - TY - JOUR AU - Zannad, F. PY - 2015 DA - 2015// TI - Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial JO - Lancet VL - 385 UR - https://doi.org/10.1016/S0140-6736(14)62225-X DO - 10.1016/S0140-6736(14)62225-X ID - Zannad2015 ER - TY - JOUR AU - Marso, S. P. PY - 2016 DA - 2016// TI - Liraglutide and cardiovascular outcomes in Type 2 diabetes JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1603827 DO - 10.1056/NEJMoa1603827 ID - Marso2016 ER - TY - JOUR AU - Marso, S. P. PY - 2016 DA - 2016// TI - Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1607141 DO - 10.1056/NEJMoa1607141 ID - Marso2016 ER -